CClinicalTrials.gg
Status unknownNCT03961230Updated May 23, 2019

Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome

A Phase 2 interventional study of Jueyin granules and Jueyin Granules Placebo in Psoriasis Vulgaris, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Status unknown at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-23.

Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

We designed this study as a multicenter, randomized, double blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of psoriasis with blood stasis syndrome.

Read the detailed description

Psoriasis is a chronic, relapsing, inflammatory, multisystem disease characterized by infiltration of inflammatory cells, hyperplasia of epidermal keratinocytes, and abnormal differentiation. Latest data estimate that the prevalence of psoriasis in adults has increased to 11.43%, which shows that the control and treatment of psoriasis is still insufficient. Recent studies showed that traditional Chinese medicine (TCM) is one of the effective methods for the treatment of psoriasis. More and more evidences support the recognition of psoriasis not only affects the skin, but also suffers a chronic multisystem inflammation. Chinese medicine believes that the blood heat is the root of the onset of psoriasis, so the treatment of psoriasis should focus on the method of clearing heat and cooling blood. Therefore, the method of promoting clearing heat and cooling blood. has always been the focus of TCM treatment and prevention of psoriasis. This multicenter, randomized, double-blind, placebo-controlled trial will provide high-quality clinical evidences for evaluating the efficacy, safety and recurrence rate of Jueyin granule, a representative prescription for the treatment of psoriasis with blood heat syndrome, in the treatment of psoriasis.

02

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

Keywords

  • Psoriasis Vulgaris
  • Jueyin granules
  • Blood heat syndrome
  • Randomized controlled trial
03

In context

Psoriasis

1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.

This study's planned enrollment of 196 is above the median of 70 across 1,447 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Shanghai Yueyang Integrated Medicine Hospital is the lead sponsor of 35 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Comply with the diagnostic criteria of Western medicine for psoriasis and the diagnostic criteria for TCM syndromes;
  2. Skin lesions involve ≤10% BSA (the lesions are mainly located in the trunk and/or limbs, palm/sole, face/scalp, vulva area is not included);
  3. Age between 18 and 65 years old;
  4. Those who voluntarily participate in the study and sign informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients with erythrodermic, arthritic, pustular or punctate psoriasis;
  2. Other active skin diseases may affect the condition assessment;
  3. Received research drugs, biological agents and immunosuppressive agents within 1 month;
  4. 2 weeks of treatment with topical glucocorticoids, phototherapy, etc.;
  5. During severe, uncontrollable local or systemic acute or chronic infections;
  6. Patients with severe systemic diseases; or clinical test indicators in one of the following conditions: alanine aminotransferase or aspartate aminotransferase increased by >1.5 times the upper limit of normal; creatinine increased by 1.5 times the upper limit of normal; blood routine indicators (white blood cell count) Any one of the red blood cell count, hemoglobin amount, and platelet count) is below the lower limit of normal; or other laboratory abnormalities are judged by the investigator to be unsuitable for participation in the trial;
  7. A history of malignant tumors and patients with primary or secondary immunodeficiency and hypersensitivity;
  8. Such surgery will be required during major surgery or study during 8 weeks;
  9. Pregnant or lactating women;
  10. A person with a history of alcohol abuse, drug abuse or drug abuse;
  11. Have a history of serious mental illness or family history;
  12. Other reasons researchers believe that it is inappropriate to participate in this research.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    Oral Chinese medicine

    Participants in experimental group will receive Jueyin granule two times daily after meals three times per week for 8 weeks.

    Drug: Jueyin granules

  • Placebo comparator
    Oral Chinese medicine placebo

    Participants in placebo group will receive Jueyin granule placebo two times daily after meals three times per week for 8 weeks.

    Drug: Jueyin Granules Placebo

Interventions

  • DrugJueyin granules

    Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.

    Also known as: Chinese Herbal Medicine

  • DrugJueyin Granules Placebo

    Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.

    Also known as: Chinese Herbal Medicine

06

What researchers measure

Primary outcomes

  1. Psoriasis area and severity index

    Psoriasis Area and Severity Index involves grading psoriatic plaques based on erythema (E), infiltration (I), desquamation (D). Severity is graded from 0-4 for each criteria (0 - none, 1 - slight, 2 - moderate, 3 - severe, and 4 - very severe). The body is divided into 4 regions, head, upper extremities, trunk, and lower extremities, and for each region, the surface area involvement is graded on a 0-6 scale (0 - 0% involvement, 1 - \<10%, 2 - 10-\<30%, 3 - 30-\<50%, 4 - 50-\<70%, 5 - 70-\<90%, 6 - 90-100%).The highest potential PASI score is 72, with higher PASI scores indicating worse psoriasis.

    Time frame: Up to 56 days after treatment.

Secondary outcomes

  1. Body surface area (BSA)

    The percentage of BSA involved in psoriasis is estimated by fingerprinting, where the entire palm of the patient represents approximately 1% of the total BSA. The number of handprints on psoriasis skin in a body part is used to determine the extent to which the body part is affected by psoriasis (%)

    Time frame: Up to 56 days after treatment.

  2. Physician Global Assessment (PGA)

    Physician Global Assessment (PGA) is scored on a 5-point scale, reflecting a global consideration of the erythema (E), infiltration (I), desquamation (D) across all psoriatic lesions. It is calculated as follows: PGA score = (E + I + D) / 3, then the score needs to be rounded to the nearest whole number \[PGA scale: Clear (0) - Very Severe (5)\].

    Time frame: Up to 56 days after treatment.

  3. Dermatology Life quality index(DLQI)

    The Dermatology Life Quality Index (DLQI) is a participant-reported questionnaire used to measure the health-related quality of life (QOL) of adults suffering from a skin disease. Scores range from 0-30, a higher score indicating a greater impact on a participant's quality of life.

    Time frame: Up to 56 days after treatment.

  4. Patient-reported quality of life (PRQoL)

    PRQoL is used to assess the impact of psoriasis on individual social life. Scores range from 0-25, a higher score indicating a greater impact on a participant's social life.

    Time frame: Up to 56 days after treatment.

  5. Visual Analogue Score (VAS)

    Visual Analog Scale (VAS) is used to measure lesion pruritus from 0 to 100 mm at eash visit (with 0 being no pruritis and 100 being maximum pruritis).

    Time frame: Up to 56 days after treatment.

  6. TCM symptom score

    The TCM symptom score is used to assess changes in blood syndrome related symptoms during treatment.

    Time frame: Up to 56 days after treatment.

07

Study locations

4 sites
  • First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
    Hefei, Anhui, China
  • Beijing Hospital of Traditional Chinese Medicine
    Beijing, Beijing, China
  • Affiliated Hospital of Gansu University of Chinese Medicine
    Nanchang, Gansu, China
  • Guangxi Zhuang Autonomous Region Dermatology Hospital
    Nanning, Guizhou, China
08

References and documents

Publications

  • Li S, Zhang C, Zhang HY, Zhou M, Wang SN, Xu R, Zhou DM, Ji YR, Lv JJ, Yin QF, Wang RP, Li W, Liu YP, Wang JF, Li B, Li X. Efficacy and Safety of Jueyin Granules for Patients with Mild-to-Moderate Psoriasis Vulgaris: Protocol for a Multicenter Randomized Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2020 Apr 9;2020:8942301. doi: 10.1155/2020/8942301. eCollection 2020. PubMed 32351609 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03961230
Lead sponsor
Shanghai Yueyang Integrated Medicine Hospital
Collaborators
Beijing Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Guangxi Zhuang Autonomous Region Dermatology Hospital
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Jun 1, 2019 (estimated)
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
May 23, 2019

Study contacts

Bin Li
Contact
18930568129@163.com
0086-021-55981301
Kan Ze
Contact
zekan1@163.com
0086-021-65161782-3137
Jia Zhou
study chair · Department of dermatology, Shanghai Yueyang Integrated Medicine Hospital, Shanghai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion